Neural Noise- CeriBell, Inc. (Nasdaq: CBLL) announced on August 3, 2026 that CMS granted a New Technology Add-on Payment (NTAP) for its Ceribell Delirium Monitor System under the Medicare Hospital Inpatient Prospective Payment System.1
- The NTAP provides up to $2,171 per eligible Medicare patient case using the Delirium Monitor System, with the add-on payment taking effect October 1, 2026.1
- The Delirium Monitor System is a point-of-care platform that continuously analyzes automated EEG segments and alerts clinicians to patterns associated with delirium.1
- The reimbursement milestone follows the system’s FDA 510(k) clearance in December 2025; Ceribell states it is the first and only FDA-cleared device for aiding delirium screening and monitoring.1
- Delirium monitoring integrates with Ceribell’s existing FDA-cleared platform for detecting nonconvulsive seizures and electrographic status epilepticus, letting providers track multiple neurological vital signs from a single bedside system.1
- Ceribell frames the NTAP as key to facilitating broader commercial access to the technology for critically ill inpatients.1